Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
TYRA
TYRA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TYRA News
Healthcare Stocks Surge in After-Hours Trading
Jan 28 2026
NASDAQ.COM
Tyra Biosciences Director Sells 246,871 Shares for $5 Million
Dec 23 2025
Fool
Tyra Biosciences Director Sells 246,871 Shares, Retains $77.6 Million Stake
Dec 23 2025
NASDAQ.COM
Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday
Dec 16 2025
Benzinga
Tyra Biosciences Appoints New Executives to Advance FGFR Drug Development
Dec 01 2025
PRnewswire
Insider at Tyra Biosciences Sells Shares Valued at $2,108,067, Recent SEC Filing Reveals
Nov 18 2025
Yahoo Finance
Tyra Biosciences Announces Participation at Upcoming Investor Events
Nov 12 2025
PRnewswire
Tyra Biosciences Reports Third Quarter 2025 Financial Results and Highlights
Nov 05 2025
PRnewswire
VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements
Oct 23 2025
NASDAQ.COM
Raymond James Begins Coverage of Tyra Biosciences with a Strong Buy Rating and Sets Price Target at $35
Sep 03 2025
Benzinga
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia
Aug 21 2025
PRnewswire
Tyra Biosciences Announces Participation at Upcoming Investor Events
Aug 20 2025
PRnewswire
Tyra Biosciences Narrows Loss in Q2
Aug 14 2025
NASDAQ.COM
Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Aug 14 2025
PRnewswire
Tyra Biosciences Announces Fireside Chat on Achondroplasia and Growth Disorders at UBS Biotech Management Live Call Series
Jul 21 2025
PRnewswire
Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025
Jul 08 2025
PRnewswire
Show More News
